AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24672232 — intervention group
Group type: EXPERIMENTAL
Intervention: C. domestica extracts 1,500 mg/day for 4 weeks
Number of subjects: 367
Study 24672232 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg/day for 4 weeks
Number of subjects: 367
Study 21831100 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 107
Study 21831100 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 107
Study 20683042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion)
Number of subjects: 24
Study 20683042 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (historical data from n=127 patients)
Number of subjects: 24
Study 17055120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (7.2 g/day, providing 1.1 g/day of 20:5 (n‐3) and 0.7 g/day of 22:6 (n‐3) fatty acids)
Number of subjects: 15
Study 17055120 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (placebo)
Number of subjects: 15
Study 15848572 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 122
Study 15848572 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 122
Study 12045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PYR) 45 mg
Number of subjects: 10
Study 12045833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10465179 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg/day) for 6 weeks
Number of subjects: 47
Study 10465179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7611726 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral, venous intradural infusions of urokinase
Number of subjects: 25
Study 2171332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin) 50 mg daily
Number of subjects: 14
Study 2171332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6123336 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.0066 mg kg‐1 i.v. (group A)
Number of subjects: 30
Study 6123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.0066 mg kg‐1 i.v. followed by almitrine 0.5 mg kg‐1 i.v. (group B)
Number of subjects: 30
Study 6123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of almitrine 0.5 mg kg‐1 and fentanyl 0.0066 mg kg‐1 (group C)
Number of subjects: 30
Study 30296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrational beliefs (IBs)
Number of subjects: 81
Study 30296958 — intervention group
Group type: COMPARATOR
Intervention: Rational beliefs (RBs)
Number of subjects: 81
Study 28198997 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative comprehensive geriatric assessment and optimization
Number of subjects: 176
Study 28198997 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative assessment
Number of subjects: 176
Study 26221410 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign
Number of subjects: 152
Study 26221410 — intervention group
Group type: COMPARATOR
Intervention: Braces
Number of subjects: 152
Study 25620331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program
Number of subjects: 82
Study 25620331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cardiac rehabilitation)
Number of subjects: 82
Study 22134132 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab (0.5, 1.5, 4.0, and 10.0 mg/kg)
Number of subjects: 0
Study 19864308 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion maintained at a target organ concentration of 1.5 ng ml‐1 until extubation
Number of subjects: 40
Study 19864308 — intervention group
Group type: COMPARATOR
Intervention: Control group (remifentanil infusion stopped at the end of surgery)
Number of subjects: 40
Study 19074684 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation (FES) with bilateral activities training
Number of subjects: 20
Study 19074684 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation with bilateral tasks
Number of subjects: 20
Study 16319704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment provided to high-stress group
Number of subjects: 127
Study 16319704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment provided to low-stress group
Number of subjects: 127
Study 16319704 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction for all patients
Number of subjects: 127
Study 11972945 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation (electronic consultation via a secure Web-based system)
Number of subjects: 93
Study 11972945 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional referral letter to the hospital outpatient clinic)
Number of subjects: 93
Study 11972945 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Number of subjects: 93
Study 9292630 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 37
Study 9292630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 37
Study 9292630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7659811 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 mcg vaginal tablet)
Number of subjects: 153
Study 7659811 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (2‐32 mU/min i.v.)
Number of subjects: 153
Study 7659811 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 153
Study 7659811 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 153
Study 7659811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 2444306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg bd)
Number of subjects: 55
Study 2444306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12473698 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.50 mg/mL rhBMP-2
Number of subjects: 450
Study 12473698 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 450
Study 29487073 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care (UC)
Number of subjects: 136
Study 29487073 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 136
Study 26506998 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical tube
Number of subjects: 70
Study 26506998 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 70
Study 24357574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day cognitive-behavioural therapy (CBT) self-confidence workshops
Number of subjects: 459
Study 24357574 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 459
Study 22416781 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 RNA genotyping
Number of subjects: 169
Study 22416781 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 DNA genotyping
Number of subjects: 169
Study 22416781 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 RNA
Number of subjects: 169
Study 22416781 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 DNA
Number of subjects: 169
Study 20597564 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight
Number of subjects: 108
Study 20597564 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily
Number of subjects: 108
Study 18414360 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.4 mg/kg)
Number of subjects: 60
Study 18414360 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg/kg)
Number of subjects: 60
Study 18414360 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 15819826 — intervention group
Group type: EXPERIMENTAL
Intervention: Digident CAD/CAM system (DIGI)
Number of subjects: 24
Study 15819826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec Inlab system (INLA)
Number of subjects: 24
Study 15819826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava system (LAVA)
Number of subjects: 24
Study 15819826 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic FPDs (control)
Number of subjects: 24
Study 12422331 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 27
Study 10325515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy for 3 or 6 months
Number of subjects: 0
Study 10325515 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7567381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-trial practice group
Number of subjects: 0
Study 7567381 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-trial practice group
Number of subjects: 0
Study 7567381 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention session
Number of subjects: 0
Study 2015969 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant DNA hGH (rhGH; 0.1 mg.kg‐1.day‐1)
Number of subjects: 32
Study 2015969 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone (0.8 mg.kg‐1.day‐1)
Number of subjects: 32
Study 2015969 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH and prednisone (combined treatment)
Number of subjects: 32
Study 2015969 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 2015969 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 32
Study 2015969 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone
Number of subjects: 32
Study 6820207 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser conisation
Number of subjects: 79
Study 6820207 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conisation
Number of subjects: 79
Study 31569274 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose flare-up protocol
Number of subjects: 131
Study 31569274 — intervention group
Group type: COMPARATOR
Intervention: Flare-up protocol
Number of subjects: 131
Study 31569274 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 131
Study 30777511 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective-context group (angry/happy faces)
Number of subjects: 0
Study 30777511 — intervention group
Group type: COMPARATOR
Intervention: Neutral-context group (male/female faces)
Number of subjects: 0
Study 28626020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 supplementation
Number of subjects: 42
Study 28626020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26854877 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures (n = 53) or implant‐supported fixed partial dentures (n = 19)
Number of subjects: 125
Study 26854877 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 125
Study 26854877 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures or implant‐supported fixed partial dentures (treatment group)
Number of subjects: 125
Study 22958543 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-seeded artificial dermis (AFD) using animal-product-free medium
Number of subjects: 5
Study 22958543 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-seeded artificial dermis (AFD)
Number of subjects: 5
Study 22438074 — intervention group
Group type: EXPERIMENTAL
Intervention: Native Hawaiian smokers
Number of subjects: 919
Study 22438074 — intervention group
Group type: EXPERIMENTAL
Intervention: Filipino and Native Hawaiian smokers
Number of subjects: 919
Study 22438074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation interventions tailored for Native Hawaiian smokers
Number of subjects: 919
Study 19641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload (500 mL of hydroxyethyl starch over 15-20 min before spinal anesthesia)
Number of subjects: 178
Study 19641050 — intervention group
Group type: COMPARATOR
Intervention: Colloid coload (identical fluid bolus of hydroxyethyl starch starting at the time of identification of cerebrospinal fluid)
Number of subjects: 178
Study 19641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload
Number of subjects: 178
Study 19641050 — intervention group
Group type: COMPARATOR
Intervention: Colloid coload
Number of subjects: 178
Study 19641050 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload and coload
Number of subjects: 178
Study 17957416 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interpreter service intervention
Number of subjects: 323
Study 17957416 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking attending physician
Number of subjects: 323
Study 17957416 — intervention group
Group type: COMPARATOR
Intervention: Usual interpreter services
Number of subjects: 323
Study 15821354 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8
Study 15821354 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 8
Study 11202125 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy (coping skills training and cognitive therapy)
Number of subjects: 120
Study 11202125 — intervention group
Group type: COMPARATOR
Intervention: Non-specific supportive therapy
Number of subjects: 120
Study 10360048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaginal Ovestin and GnRh analogues (Zoladex)
Number of subjects: 12
Study 10360048 — intervention group
Group type: COMPARATOR
Intervention: GnRh analogues alone (control group)
Number of subjects: 12
Study 7846192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 40 mg
Number of subjects: 18
Study 7846192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 20 mg
Number of subjects: 18
Study 7846192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (20 and 40 mg)
Number of subjects: 18
Study 7846192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2903659 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (n = 12), continuous intravenous infusion, titrated from 2 to 24 mg/min
Number of subjects: 23
Study 2903659 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (n = 11), oral, dose increased every 6 hours by 50 to 100%
Number of subjects: 23
Study 30982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat samples (17 different samples, 670 g/kg of each wheat sample in diet)
Number of subjects: 800
Study 30982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat samples (specific two samples)
Number of subjects: 800
Study 30982351 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat samples (general)
Number of subjects: 800
Study 27547871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered corticosteroids (stopped after day 10)
Number of subjects: 1081
Study 27547871 — intervention group
Group type: COMPARATOR
Intervention: No steroids after intraoperative bolus
Number of subjects: 1081
Study 26032567 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality job interview training (VR‐JIT)
Number of subjects: 32
Study 26032567 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 32
Study 23828748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 20
Study 23828748 — intervention group
Group type: COMPARATOR
Intervention: Balloon tamponade
Number of subjects: 20
Study 21767283 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5-50 mg)
Number of subjects: 38
Study 21767283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration without post and cusp capping
Number of subjects: 75
Study 19801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration without post but with cusp capping
Number of subjects: 75
Study 19801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration with post but without cusp capping
Number of subjects: 75
Study 19801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration with post and cusp capping
Number of subjects: 75
Study 19801245 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact teeth)
Number of subjects: 75
Study 16895881 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter-based diet
Number of subjects: 14
Study 16895881 — intervention group
Group type: EXPERIMENTAL
Intervention: ROO, HPSO, butter, VEFO
Number of subjects: 14
Study 16895881 — intervention group
Group type: EXPERIMENTAL
Intervention: VEFO omitted from analysis
Number of subjects: 14
Study 16895881 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial concentrations of triacylglycerol
Number of subjects: 14
Study 15051213 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion eye drop (EED)
Number of subjects: 15
Study 15051213 — intervention group
Group type: COMPARATOR
Intervention: Nonpreserved saline (Control)
Number of subjects: 15
Study 10745146 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens
Number of subjects: 0
Study 10745146 — intervention group
Group type: COMPARATOR
Intervention: No contact lens (Control)
Number of subjects: 0
Study 8814427 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seropositive
Number of subjects: 100
Study 8814427 — intervention group
Group type: COMPARATOR
Intervention: HIV-seronegative
Number of subjects: 100
Study 8814427 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seropositive with advanced immunosuppression
Number of subjects: 100
Study 1383618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg up to 100 mg daily)
Number of subjects: 257
Study 1383618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg up to 80 mg daily)
Number of subjects: 257
Study 1383618 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 257
Study 3905561 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg D-penicillamine daily
Number of subjects: 56
Study 3905561 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg D-penicillamine daily
Number of subjects: 56
Study 3905561 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (both doses)
Number of subjects: 56
Study 30832717 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-navigation (MI-NAV) intervention
Number of subjects: 80
Study 30832717 — intervention group
Group type: COMPARATOR
Intervention: Standard of care condition
Number of subjects: 80
Study 27966575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 16
Study 27966575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 16
Study 27966575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Vitamin D2 and D3
Number of subjects: 16
Study 27966575 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 26073333 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-only pill
Number of subjects: 64
Study 26073333 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel-only pill
Number of subjects: 64
Study 24360131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants
Number of subjects: 182
Study 24360131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 182
Study 24360131 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing (NH)
Number of subjects: 182
Study 24360131 — intervention group
Group type: COMPARATOR
Intervention: Sensorineural hearing loss (SNHL)
Number of subjects: 182
Study 22801255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training on the vascular intervention simulation trainer simulator
Number of subjects: 21
Study 22801255 — intervention group
Group type: COMPARATOR
Intervention: Expert evaluation
Number of subjects: 21
Study 20003224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus optimal medical management
Number of subjects: 11
Study 20003224 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 11
Study 17524779 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplant (AMT)
Number of subjects: 30
Study 17524779 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival advancement
Number of subjects: 30
Study 15334389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (60 microg subcutaneous premeal injections 3 times daily for 5 days, IV infusion of 16 microg/h)
Number of subjects: 18
Study 15334389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous premeal injections 3 times daily for 5 days, IV infusion of placebo)
Number of subjects: 18
Study 12845247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (22 g for 48 hours)
Number of subjects: 194
Study 11829830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola compound (RCO) 4 grams daily for 3-15 days after admission and 5-7 days post-operation
Number of subjects: 104
Study 11829830 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 104
Study 8638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 8638026 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 1925418 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine 800 mg orally daily for six weeks
Number of subjects: 44
Study 1925418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7044411 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir (Zovirax)
Number of subjects: 93
Study 7044411 — intervention group
Group type: COMPARATOR
Intervention: 3% adenosine arabinoside (ara-A, Vidarabine)
Number of subjects: 93
Study 3925464 — intervention group
Group type: EXPERIMENTAL
Intervention: l-histidine 3g/day for 7 days
Number of subjects: 18
Study 3925464 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18